Tue Jan 26 2021

SuPARnostic® may soon become the first tool for guiding COVID-19 drug treatment. It’s already in use in Europe for managing COVID-19 patients. We’re collaborating with the Hellenic Institute for the Study of Sepsis (HISS) on a study. This will test if suPARnostic® can help start anakinra treatment early for COVID-19.

A 2020 study, now under review, shows promise. It compared 130 COVID-19 patients treated with anakinra against 130 who weren’t. The treated group had fewer cases of severe respiratory failure (22.3% vs. 59.2%) and lower 30-day mortality rates (11.5% vs. 22.3%).

HISS is conducting a study to verify these results. This phase III trial will assess the benefits of using suPAR levels to guide early anakinra treatment in 600 patients across Greece and Italy. The focus is on clinical improvement over 28 days. It also looks at hospital costs, discharge times, and side effects. We are supplying the test kits.

Since 2019, we’ve expanded the use of suPARnostic® TurbiLatex and Quick Triage in European hospitals for COVID-19. Production has increased to meet the demand for COVID-19 patient care.

“If the interim results are validated in the randomized clinical trial, the implication for healthcare professionals working with the management of COVID-19 patients can be significant.”

Evangelos Giamarellos-Bourboulis,
MD, PhD., Hellenic Institute for the Study of Sepsis

Evangelos Giamarellos-Bourboulis, MD, Ph.D., Hellenic Institute for the Study of Sepsis, said:

“Our interim analysis of 130 patients using suPAR-guided anakinra treatment of COVID-19 patients showed promising results in significantly decreasing mortality, the incidence of severe respiratory failure, and the median cost of hospitalization. If the interim results are validated in the randomized clinical trial, the implication for healthcare professionals working with the management of COVID-19 patients can be significant.”

Jakob Knudsen, Chief Executive Officer of ViroGates, says:

”We are delighted to enter a partnership with HISS to clinically validate our suPARnostic® product as potentially the first companion diagnostic device used in the process to assess patients eligible for treatment for COVID-19 disease. The hospital systems currently face severe crowding in acute and intensive care functions. The ability to identify COVID-19 patients for early treatment can potentially save lives, reduce costs, and ease the burden on national health care systems.”

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates